clinical trial · NCT06712628
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
AbbVie·—·recruiting·n = 678
Moderate to Severe Rheumatoid Arthritis
brief summary
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany. Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.
started
Nov 7, 2024
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Feb 17, 2026
official title
Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol